M.E. Allison & CO. Inc. Has $881,000 Stock Position in Pfizer Inc. $PFE

M.E. Allison & CO. Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 44.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 36,348 shares of the biopharmaceutical company’s stock after buying an additional 11,186 shares during the period. M.E. Allison & CO. Inc.’s holdings in Pfizer were worth $881,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter worth $27,000. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter worth $28,000. North Capital Inc. bought a new position in Pfizer in the first quarter worth $28,000. WPG Advisers LLC bought a new position in Pfizer in the first quarter worth $35,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer in the first quarter worth $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.35.

Pfizer Stock Down 1.7%

Shares of NYSE PFE opened at $24.81 on Monday. The stock has a market cap of $141.03 billion, a PE ratio of 13.19, a PEG ratio of 0.82 and a beta of 0.55. The business has a fifty day moving average of $24.86 and a two-hundred day moving average of $24.12. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.